Pancreatic Neoplasms
Conditions
Brief summary
This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with sintilimab and AG in first-line therapy of patients with locally advanced or metastatic pancreatic cancer.
Interventions
DRUGSurufatinib
250mg, qd, po, 21 days for a cycle
DRUGSintilimab
200mg, ivgtt, d1, 21 days for a cycle, up to 2 years
DRUGAG
nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Informed consent has been signed 2. Histologically or cytologically confirmed unresectable, locally advanced or metastatic pancreatic cancer 3. Age ≥ 18 years, ≤75 years, male or female 4. ECOG PS：0-1, expected overall survival ≥12 months 5. Patients who have not previously received systemic therapy for locally advanced or metastatic pancreatic cancer 6. Patients with distant metastases after surgery, who have received one regimen of adjuvant chemotherapy and have recurred \> 6 months from adjuvant therapy can be enrolled 7. Patients must have at least one measurable liver metastases (RECIST 1.1) 8. No serious organic diseases of the heart, lungs, brain and other organs 9. Patients must have adequate organ and bone marrow function 10. Women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration
Exclusion criteria
1. Participated in clinical trials of other anti-tumor drugs within 4 weeks before enrollment 2. Previously received VEGFR inhibitors or immune checkpoint inhibitors 3. Patients with BRCA1/2 germline mutations 4. Patients with obstructive jaundice but less than expected jaundice 5. Patients had other malignant tumors in the past 5 years, except for the cured skin basal cell carcinoma and cervical carcinoma in situ 6. Patients previously had brain metastasis or current brain metastasis 7. Investigator determines that the liver metastases account for 70% or more of the total liver volume 8. Received any operation (except biopsy) or invasive treatment or operation (except venous catheterization, puncture and drainage, internal/external drainage surgery for obstructive jaundice, etc.) within 4 weeks before enrollment 9. Received local anti-tumor therapy such as hepatic artery interventional embolization, cryoablation or radiofrequency ablation of liver metastases within 4 weeks before enrollment 10. Clinically significant electrolyte abnormality 11. Patient currently has uncontrolled hypertension, defined as: systolic blood pressure \> 140mmHg or diastolic blood pressure \> 90mmHg 12. Proteinuria ≥ 2+ (1.0g/24hr) 13. Patients whose tumor is highly likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study period as judged by the investigator 14. Have evidence or history of bleeding tendency within 3 months, Significant bleeding symptoms or a clear bleeding tendency within 3 months before enrollment 15. Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; NYHA classification \> 2 Grade; ventricular arrhythmia requiring medical therapy; ECG showing QTc interval ≥ 480 ms 16. Active or uncontrolled serious infection (≥CTCAE grade 2 infection) 17. Unrelieved toxic reactions ≥ CTCAE grade 2 due to any previous anticancer treatment, excluding alopecia, lymphopenia and neurotoxicity of ≤ grade 2 caused by oxaliplatin 18. Pregnant or lactating women 19. Any other disease, with clinically significant metabolic abnormalities, physical examination abnormalities or laboratory abnormalities, according to the judgment of investigator that the patient is not suitable for the the study drug (such as having epileptic seizures and require treatment), or would affect the interpretation of study results, or put patients at high risk 20. Clinical confirmed human immunodeficiency virus (HIV) infection, history of clinically significant liver disease, including viral hepatitis (hepatitis B / C (HBV DNA Positive\[1×104 copies/mL or \>2000 IU/ml\], HCV RNA positive\[\>1×103 copies/mL\]), or other hepatitis, cirrhosis\]) 21. Patients with autoimmune disease or suspected autoimmune disease (including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, enteritis, multiple Sclerosis, vasculitis, glomerulonephritis, uveitis, hypophysitis, hyperthyroidism, etc.) 22. Patients who are allergic or suspected to be allergic to the study drug or similar drugs 23. Patients have other factors that may affect the results of the study or cause the study to be terminated halfway, such as alcoholism, drug abuse, other serious diseases (including mental diseases) that require concomitant treatment, and serious laboratory abnormalities. Accompanied by family or social factors, which will affect the safety of patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate (ORR) | up to 24 months | Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | up to 24 months | PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator |
| disease control rate (DCR) | up to 24 months | DCR was defined as the percentage of participants who have a confirmed complete response（CR） or partial response（PR） or stable disease（SD） per RECIST 1.1 as assessed by investigator |
| overall survival (OS) | up to 24 months | OS is the time from enrollment to death due to any cause. |
| Molecular markers and imaging parameters predicting therapeutic efficacy | up to 24 months | Peripheral blood was collected from patients during the screening period, treatment period and safety follow-up period, and serum pathological examinations were performed; tumor imaging evaluation added elastography |
| adverse events (AE) | up to 24 months | overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use. |
Countries
China
Outcome results
None listed